NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
Rhea-AI Summary
NetraMark (OTCQB: AINMF) announced acceptance of a peer‑reviewed paper, “Explainable AI‑Driven Precision Clinical Trial Enrichment,” in npj Digital Medicine on Dec 8, 2025. The study demonstrates the NetraAI platform using data from a National Institute of Mental Health Phase II ketamine trial in treatment‑resistant depression to identify interpretable Model Derived Subgroups (MDS) that could inform precision enrichment.
The paper highlights NetraAI’s use of explainable, mathematically grounded AI, dynamical‑systems modeling, long‑range‑memory feature learning, and LLM‑augmented explainability to improve clinical interpretability and trial decision‑making.
Positive
- Peer‑review acceptance in npj Digital Medicine (Nature portfolio)
- Demonstrated explainable AI on NIMH Phase II ketamine trial data
- Interpretable Model Derived Subgroups (Personas) identified for enrichment
- Claims of methods supporting regulatory‑grade explainability, reproducibility, traceability
Negative
- Demonstration limited to a single NIMH Phase II ketamine trial dataset
News Market Reaction – AINMF
In the Dec 8 session, AINMF declined 6.33%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Technology validation | Positive | -6.3% | Peer-reviewed NetraAI publication in npj Digital Medicine demonstrating precision enrichment. |
| Aug 05 | Clinical trial contract | Positive | +0.0% | Contract with Asklepion to use NetraAI in Phase III pediatric cardiac study. |
| Jul 31 | Conference participation | Positive | -2.5% | Participation in Canaccord Genuity growth conference to highlight NetraAI platform. |
| Jul 30 | Partnership announcement | Positive | -0.9% | Partnership with Pentara to launch AI-powered site intelligence and Paradox Risk score. |
| Jul 28 | Clinical trial support | Positive | -3.4% | Agreement with AlgoTx using NetraAI to enhance ATX01 clinical trial design. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive partnership, conference, and technology-validation news has often coincided with flat to negative next-day price moves, indicating a pattern of weak upside follow-through on seemingly constructive announcements.
This announcement of NetraAI’s publication in npj Digital Medicine fits a multi-month pattern of showcasing the platform’s clinical-trial applications. Since late July 2025, NetraMark announced contracts with AlgoTx and Asklepion for clinical-trial design support, a partnership with Pentara to monitor trial integrity, and attendance at Canaccord’s 45th Growth Conference. Despite these developments, share reactions were modest or negative, including a 6.33% drop following today’s publication news, underscoring muted market recognition of these milestones so far.
Key Terms
model derived subgroups (mds) medical
dynamical-systems modeling technical
long-range-memory feature learning technical
large-language-model technical
placebo medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that its peer-reviewed paper, “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” has been accepted for publication in npj Digital Medicine, part of the Nature Portfolio.
The paper presents how NetraMark’s proprietary NetraAI platform applies explainable, mathematically grounded artificial intelligence to identify patient subpopulations that drive therapeutic response in small, heterogeneous clinical-trial datasets. Using data from a National Institute of Mental Health (NIMH) Phase II ketamine trial in treatment-resistant depression, NetraAI uncovered interpretable “Personas” or “Model Derived Subgroups (MDS)” that may inform precision-enrichment strategies across psychiatry and other therapeutic areas.
The research was co-authored by investigators from the NIMH, part of the U.S. National Institutes of Health, including Dr. Elizabeth D. Ballard and Dr. Carlos A. Zarate Jr., alongside scientists from NetraMark Corp. and academic collaborators. (NIMH participation does not imply endorsement by the U.S. Government.)
“Acceptance of this paper for publication by npj Digital Medicine affirms the progress we’ve made toward building an AI engine purpose-built for clinical trials. Our work demonstrates a data-driven methodology with meaningful improvements in performance and clinical interpretability,” said Dr. Joseph Geraci, Chief Scientific and Technical Officer of NetraMark.
Dr. Luca Pani, Chief Innovation and Regulatory Officer at NetraMark, added, "This publication bridges scientific innovation with the rigorous expectations of regulatory science. By embedding explainability, reproducibility, and traceability into its core, NetraAI provides regulators and clinical investigators with credible tools designed to support modern clinical trial design and decision-making.”
The study highlights how NetraAI’s integration of dynamical-systems modeling, long-range-memory feature learning, and its ability to augment large-language-model explainability can enhance clinical trial decision-making, reduce placebo interference, and optimize trial enrichment.
The peer-reviewed publication is available at https://www.nature.com/articles/s41746-025-02143-7.
About NetraAI
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential applications and benefits of the NetraAI platform; the ability of NetraAI to identify patient subpopulations, inform precision-enrichment strategies, enhance clinical trial decision-making, reduce placebo interference, and optimize trial enrichment; the capabilities of the Company's technology; and the Company's business objectives and development plans. NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Contact Information: Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
